NIH R01 · 2024
Replication Stress and DNA Damage Response Drives ESR1 Mutant Metastasis
Our research focus is estrogen receptor (ER)-positive luminal breast cancer, representing 75% of primary breast cancer patients, who are prescribed adjuvant endocrine therapy (ET) with hormonal agents. While recurrences are delayed by the use of ET, resistance can evolve with the development of metastatic breast cancer (MBC) in about one-fourth of ER-positive patients. MBC patients acquire ESR1 mutations in a significant percentage of cases. Our overall goal is to identify new therapeutic vulnerabilities in ESR1m preclinical models that can effectively block distant metastatic progression. Our proposal is highly translational. We hypothesize that acquired ESR1m function as activated…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.